Background: Exsomes are special capsules including proteins, DNA, RNA, etc. They have great important role in Cell Growth, Cell Invasion, Cell Differentiation. How to transfer the messages to tumor cells each other and influence tumor cells invasion is hard question. Method: First, exosomes involved in the division and proliferation of cancer cells were detected in lung cancer cell lines. Second, the animal model of lung cancer was made, and tumor specimens were regularly cut to detect the quantitative and qualitative changes of exosomes in tumor cells, so as to analyze the changes of exosomes in tumor growth. Thirdly, specific exosomes were calibrated and tracked to inhibit the secretion of specific exosomes and observe the division and growth of tumor cells. Results: The secretion of exosomes significantly affected the pathological and physiological mechanism of lung cancer cell division, differentiation, growth and invasion. Conclusion: Exosomes are important messengers that affect tumor cells, but how the messengers send signals, how they affect the mechanism of the tumor cells, and how to turn the "messenger" into a "sentinel" that monitors tumors is a long way off. Method: Consecutive patients were retrospectively enrolled and serial imaging were intensively examined. Disease progression in original sites (primary/metastatic), new sites, or both, are classified as original failure (OF), distant failure (DF) and ODF, respectively. Progression free survival, from crizotinib initiation to the first disease progression, and from that to the second disease progression, were calculated as PFS1 and PFS2. Results: Ninety-three patients with adequate imaging and measurable disease were identified. Fifty-seven patients received crizotinib as first-line therapy, while the remaining 36 patients had 1-2 lines of prior chemotherapy, with or without LTs. With a median follow up of 22.0 (range, 2.0-72.0) months, 52 patients had crizotinibtreatment failure, with a median PFS1 of 11.5 (95%CI 9.8-13.2) months. The frequencies of OF, ODF, and DF, were 50.0%, 26.9%, and 23.1%, respectively. Histology, primary tumor size and presence of BBM, were independently associated with OF, using competing risks analyses. The brain was the most common site of initial disease progression. Patients with BBM had a significant higher possibility developing multiple-progressive lesions in the brain (p¼0.002). Brain radiation before crizotinib could alter the disease failure patterns and improve PFS1 among patients with BBM (p¼0.006). Of note, four (50.0%) of the eight patients who had baseline oligo-metastatic cranial
Method: Consecutive patients were retrospectively enrolled and serial imaging were intensively examined. Disease progression in original sites (primary/metastatic), new sites, or both, are classified as original failure (OF), distant failure (DF) and ODF, respectively. Progression free survival, from crizotinib initiation to the first disease progression, and from that to the second disease progression, were calculated as PFS1 and PFS2. Results: Ninety-three patients with adequate imaging and measurable disease were identified. Fifty-seven patients received crizotinib as first-line therapy, while the remaining 36 patients had 1-2 lines of prior chemotherapy, with or without LTs. With a median follow up of 22.0 (range, 2.0-72.0) months, 52 patients had crizotinibtreatment failure, with a median PFS1 of 11.5 (95%CI 9.8-13.2) months. The frequencies of OF, ODF, and DF, were 50.0%, 26.9%, and 23.1%, respectively. Histology, primary tumor size and presence of BBM, were independently associated with OF, using competing risks analyses. The brain was the most common site of initial disease progression. Patients with BBM had a significant higher possibility developing multiple-progressive lesions in the brain (p¼0.002). Brain radiation before crizotinib could alter the disease failure patterns and improve PFS1 among patients with BBM (p¼0.006). Of note, four (50.0%) of the eight patients who had baseline oligo-metastatic cranial disease but did not receive prior brain radiation, developed multipleprogressive disease in the brain, while none of the four patients who had baseline oligo-metastatic cranial disease and received prior brain stereotactic radiosurgery developed multiple-progressive disease in the brain. On the other hand, extra-cranial LT before crizotinib was not associated with PFS1 (p¼0.223). Thirty-five (67.3%) of the 52 patients with disease failure to crizotinib were eligible for certain kind of radiotherapy. By the time of data cut-off, 28 patients had second disease progression, with a median PFS2 of 7.0 (95% CI 5.4-8.6) months. Patients who received LT after RECIST-defined disease progression to crizotinib had a significant longer PFS2 (p¼0.003). In addition, patients received any LT during their treatment course had a significant longer overall survival (p¼0.048). Conclusion: Among patients with BBM, brain radiotherapy before crizotinib provide considerable clinical benefits. Conversely, deferring extra-cranial local therapies until after initial crizotinib-treatment failure and adopting regular surveillance may be a better treatment strategy for metastatic lesions outside the brain. Background: With the development of multimodality therapy for tumor, the survival for patients with lung cancer has not been adequately evaluated. But a general overview of changes in survival is missing. Method: We analyzed lung cancer patients enrolled from the Surveillance, Epidemiology, and End Results (SEER) registry through January 1988 to December 2015. 1, 2 and 5-year survival rates were done using SEER*Stat software 8.3.5. Incidence and mortality rates were calculated for twelve age groups (25-29, 30-34,., 80-84) , presented per 100 000 person-years, and age-adjusted to the 2000 US standard population. The magnitude and direction of temporal trends were quantified using the Joinpoint Regression Program (version 4.6.6.0), which takes trend data allow to estimate the simplest joinpoint model that the data allow to estimate the annual percent change (APC) and average annual percent change (AAPC). All statistical tests were two-sided, and P values < 0.05 were considered statistically significant. R 3.5.0 was used when auxiliary calculations and drawings were needed. Results: The 1,2,5-year survival rates of different subgroups were shown. We could find compared with men and black race, women and non-black race has a better survival, whereas the survival rate of black patients increased rapidly from 2006. Compared with old patients, younger patients had better survivals. The survival rate in age groups 25-44 years and 65-84 years increased faster than the age group 45-64 years. For different histology types, all stages of all histology types increased, except for stage 0-2 squamous cell carcinoma which had a declining trend from 2004. Though the survival rate of small cell lung cancer improved continuously, no joinpoint was found. Conclusion: With the development of diagnostic and therapeutic techniques, the survival rate of lung cancer is gradually increasing except for stage 0-2 squamous cell carcinoma. But the joinpoint was not many, no joinpoint was found in small cell lung cancer. Indicated that there are fewer major medical events that prolong survival. Keywords: lung cancer, Adenocarcinoma, Squamous cell carcinoma, Survival
